Denmark’s Breye Therapeutics Secures €67.5 Million to Advance Oral Retinal Therapies
Breye Therapeutics has closed an oversubscribed €67.5 million Series A round, signalling strong investor confidence in EU biopharma innovation.
Breye Therapeutics, a Danish biopharmaceutical company developing oral treatments for retinal diseases, has raised €67.5 million in an oversubscribed Series A financing round, according to the company and investors.
The round was co-led by Mission BioCapital and Novo Holdings, with additional participation from existing backer Sound Bioventures and new investors. The substantial fundraising will allow Breye Therapeutics to accelerate the development of its pipeline of oral therapies targeting early intervention in retinal conditions.
The new funding arrives as the European Union intensifies its focus on health innovation, particularly in the biopharmaceutical sector. Investor appetite for promising EU-based biotech ventures is reflected in the oversubscription of the round, signalling growing confidence in the region’s capacity to deliver treatment breakthroughs.
Breye Therapeutics aims to address unmet needs in the retinal disease market, an area marked by significant patient demand and competition from established global players. The company’s focus on oral therapies for early-stage intervention positions it to potentially shift the treatment paradigm away from more invasive procedures currently used for retinal disorders.
According to the company, the capital injection will support advancement of its clinical pipeline and position Breye as a potential leader in the European retinal therapy market. While specific therapy candidates and development timelines were not disclosed, the funding underscores the opportunity for EU biopharma companies to attract major investment by pursuing differentiated therapeutic approaches.
Analysts note that regulatory pathways and competition remain key challenges for Breye and its peers. However, the company’s ability to draw new and existing investors—particularly from health-focused funds—reflects the broader momentum in European health innovation and the potential for further investment inflows into the sector.
